News from the FDA/CDC

FDA Expands Darzalex Faspro Indication in Myeloma


 

The US Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research and Development LLC) in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma.

Approval followed priority review and was based on efficacy and safety findings from the open-label PERSEUS trial involving 709 patients under age 70 years who were randomized to receive bortezomib, lenalidomide, and dexamethasone alone or in combination with daratumumab and hyaluronidase-fihj, according to the FDA.

Compared with bortezomib, lenalidomide, and dexamethasone alone, the addition of daratumumab and hyaluronidase-fihj resulted in a 60% reduction in the risk for disease progression or death (hazard ratio, 0.40). Median progression-free survival was not reached in either group.

Adverse reactions occurring in ≥ 20% of patients were peripheral neuropathy, fatigue, edema, pyrexia, upper respiratory infection, constipation, diarrhea, musculoskeletal pain, insomnia, and rash.

The recommended dosage for this indication is 1800 mg daratumumab and 30,000 units hyaluronidase, according to the full prescribing information.

Daratumumab and hyaluronidase-fihj, which was first approved in 2020, has a range of other indications in multiple myeloma.

A version of this article first appeared on Medscape.com.

Recommended Reading

ASCO 2024: Treating Myeloma Just Got More Complicated
MDedge Hematology and Oncology
New Tools for Monitoring Multiple Myeloma
MDedge Hematology and Oncology
Cancer Drug Shortages Continue in the US, Survey Finds
MDedge Hematology and Oncology
Time Warp: Fax Machines Still Common in Oncology Practice. Why?
MDedge Hematology and Oncology
Urticaria Linked to Higher Cancer Risk, Study Finds
MDedge Hematology and Oncology
Weight Loss Drugs Cut Cancer Risk in Diabetes Patients
MDedge Hematology and Oncology
Should Cancer Trial Eligibility Become More Inclusive?
MDedge Hematology and Oncology
Greater Transparency of Oncologists’ Pharma Relationships Needed
MDedge Hematology and Oncology
FDA Expands Darzalex Faspro Indication in Myeloma
MDedge Hematology and Oncology
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
MDedge Hematology and Oncology